Pulling Back the Curtain: Vip Viprakasit, MD, DPhil
In more from our interview with Dr. Viprakasit, he speaks about the advantages of working in a limited-resource setting and the importance of international...
Let’s Get Cooking: Jonathan Hoggatt, PhD
In more from our interview with Dr. Hoggatt, he talks about the chocolate chip cookie experiment that started his obsession with cooking.
Pulling Back the Curtain: Richard W. Childs, MD
Hear more from our interview with Dr. Childs, where he talks about his inventive career in medicine and the best and worst parts of his...
Pulling Back the Curtain: Angela Thomas, OBE, PhD
Hear more from our interview with Dr. Thomas, where she talks about "converting" trainees to pediatric hematology and offers career advice for early-career hematologists.
Pulling Back the Curtain: Allison Rosenthal, DO
Hear more from our interview with Dr. Rosenthal, where she talks about the best career advice she's ever received and the best (and worst) parts of...
Expanding Acalabrutinib to Waldenström Macroglobulinemia
Roger Owen, MRCP, MRCPath, MD, presents phase II data of the selective Bruton tyrosine kinase inhibitor, which showed “exceptional response rates” in both treatment-naïve...
Weekly Carfilzomib Dosing Superior to Twice-Weekly Dosing
James Berenson, MD, discusses results from a trial evaluating less-frequent dosing of carfilzomib for patients with myeloma. Once-weekly dosing was superior, but the mechanisms...
Enhancing Ibrutinib With Rituximab in Waldenström Macroglobulinemia
Combining ibrutinib with rituximab led to longer progression-free survival, compared with ibrutinib alone, in patients with Waldenström macroglobulinemia. Meletios Dimopoulos, MD, shares results from...
Does Blinatumomab Affect CAR T-Cell Therapy Response?
In new data from ZUMA-3, patients with acute lymphocytic leukemia responded to CD19-targeting CAR T-cell therapy, regardless of prior CD19-targeting therapy with blinatumomab. Bijal...
Venetoclax Plus Carfilzomib: A New Wave of Myeloma Treatment
Luciano Costa, MD, talks about the combination of venetoclax and carfilzomib, which led to an 83% response rate in patients with relapsed and heavily-refractory...
Current Issue
February 2019, Volume 5, Issue 3
This issue features a look at the unique challenges of developing treatments for orphan diseases, more coverage of the 2018 ASH annual meeting, and more.
